<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02345096</url>
  </required_header>
  <id_info>
    <org_study_id>OP090414.LES</org_study_id>
    <nct_id>NCT02345096</nct_id>
  </id_info>
  <brief_title>Effect of Saccharomyces Cerevisiae on Improving the Effectiveness of Conventional Treatment of Vulvo-vaginal Candidiasis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo Controlled Study to Evaluate the Effect of Saccharomyces Cerevisiae on Improving the Effectiveness of Conventional Treatment of Vulvo-vaginal Candidiasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lesaffre International</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eurofins Optimed</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lesaffre International</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the effect of a specific strain of Saccharomyces cerevisiae on&#xD;
      improving the effectiveness of conventional treatment of vulvo-vaginal candidiasis. This is a&#xD;
      randomized, double-blind, placebo-controlled study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment difficulties&#xD;
  </why_stopped>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Enumeration of Candida albicans in a vaginal sampling</measure>
    <time_frame>up to 2 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Vulvo-vaginal Candidiasis</condition>
  <arm_group>
    <arm_group_label>Saccharomyces cerevisiae CNCM I-3856</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In this arm, subjects will be asked to consume one capsule of Saccharomyces cerevisiae CNCM I-3856 per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In this arm, subjects will be asked to consume one capsule of placebo per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Saccharomyces cerevisiae</intervention_name>
    <arm_group_label>Saccharomyces cerevisiae CNCM I-3856</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Premenopausal female patient with a clinical diagnosed vulvo-vaginal candidiasis&#xD;
&#xD;
          -  Regularly menstruating women with normal gynaecological status&#xD;
&#xD;
          -  Patient must use a contraception method&#xD;
&#xD;
          -  Having given a written informed consent prior to selection&#xD;
&#xD;
          -  Covered by Health Insurance System and / or in compliance with the recommendations of&#xD;
             National Law in force relating to biomedical research.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breast feeding.&#xD;
&#xD;
          -  Tumors in the genital tract or beast.&#xD;
&#xD;
          -  Hypersensitivity to the study product.&#xD;
&#xD;
          -  Uterine or vaginal bleeding of unknown origin.&#xD;
&#xD;
          -  Use of systemic or intravaginal antibiotic or antifungal agents in the previous 14&#xD;
             days.&#xD;
&#xD;
          -  Concomitant medication with antimycotics for other diagnoses.&#xD;
&#xD;
          -  Woman with known transmitted infections such as Neisseria gonorrhoea, Chlamydia&#xD;
             trachomatis, Treponema pallidum, herpes simplex, Trichomonas vaginalis, human&#xD;
             papilloma virus, HIV 1 or 2.&#xD;
&#xD;
          -  Immunocompromised individuals.&#xD;
&#xD;
          -  Subjects not willing to stop taking probiotics in the form of dietary supplements or&#xD;
             convenient goods&#xD;
&#xD;
          -  Subject who, in the judgment of the Investigator, is likely to be non-compliant or&#xD;
             uncooperative during the study, or unable to cooperate because of a language problem,&#xD;
             poor mental development.&#xD;
&#xD;
          -  Subject under administrative or legal supervision.&#xD;
&#xD;
          -  Subject who participate to a previous study within 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Cherbut, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Independant gynecologist</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eurofins Optimed</name>
      <address>
        <city>Gi√®res</city>
        <zip>38610</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>January 19, 2015</study_first_submitted>
  <study_first_submitted_qc>January 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2015</study_first_posted>
  <last_update_submitted>December 2, 2016</last_update_submitted>
  <last_update_submitted_qc>December 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Candidiasis, Vulvovaginal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

